Programmed death-1 checkpoint blockade in acute myeloid leukemia.

ABSTRACT:

Introduction

Immune checkpoints are regulatory pathways induced in activated T lymphocytes that regulate antigen responsiveness. These immune checkpoints are hijacked by tumors to promote dysfunction of anti-tumor effector cells and consequently of tumor escape from the host immune system.

Areas covered

Programmed death-1/programmed death ligand (PD-1/PDL-1), a checkpoint pathway, has been extensively investigated in leukemia mouse models. Expression of PD-1 on the surface of activated immune cells and of its ligands, PD-L1 and PD-L2, on leukemic blasts has been documented. Clinical trials with PD-1 inhibitors in patients with hematological malignancies are ongoing with promising clinical responses.

Expert opinion

Therapy of hematological cancers with antibodies block

SUBMITTER: Sehgal A 

PROVIDER: S-EPMC4778424 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature